Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corp (NQ: ADPT )

5.930 -0.560 (-8.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adaptive Biotechnologies Corp

< Previous 1 2 3 4 5 6 Next >
Smaller Cap Biotechs Are In Season: How Are We Doing?
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
From Adaptive Biotechnologies
Via GlobeNewswire
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
From Adaptive Biotechnologies
Via GlobeNewswire
Jabil Posts Upbeat Earnings, Joins Micron Technology, Southwest Airlines And Other Big Stocks Moving Higher On Thursday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Down Over 2%; US Initial Jobless Claims Fall
Via Benzinga
Exposures Fossil Fuels
A Biotech Breakout Will Be Led By Small Caps
It’s hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever. 
Via Talk Markets
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies 
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
3 Precision Medicine Stocks Tailoring Treatments
With technological developments pushing the boundaries of healthcare, these are the precision medicine stocks to consider. 
Via InvestorPlace
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
From Adaptive Biotechnologies
Via GlobeNewswire
Cathie Wood-Led Ark Invest Scoops Up $5.16M Worth Of Palantir Shares Amid Raging AI Fervor
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Trading SMID Biotech Stocks In A Volatile Market
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers 
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
Mighty Mites: 3 Small-Cap Stocks Packing a Powerful Punch
While small-cap stocks to buy present a higher-risk profile, these ideas may also pack considerable punch for their size. 
Via InvestorPlace
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor keeps adding to some of her favorite falling stocks. 
Via The Motley Fool
Why Adaptive Biotechnologies Topped the Market Today
A double beat on earnings, plus positive adjustments to certain guidance items, lifted the company's shares. 
Via The Motley Fool
ADPT Stock Earnings: Adaptive Biotechnologies Beats EPS, Beats Revenue for Q1 2024
ADPT stock results show that Adaptive Biotechnologies beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Adaptive Biotechnologies Reports First Quarter 2024 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Netflix, ON Semiconductor And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Names New CFO Preserves Strong Capital Position
Adaptive Biotechnologies announces strategic restructuring to enhance independence and financial strength. 
Via Benzinga
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
Announces CFO transition 
From Adaptive Biotechnologies
Via GlobeNewswire
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings. 
Via Benzinga
The 7 Best Penny Stocks to Buy in Q2 2024
Discover seven penny stocks to buy primed for significant gains in Q2 2024. Don't miss out on these picks or your portfolio could suffer. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.